Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pioglitazone + atorvastatin
- Development stage
- Unknown
- Lead developer
- Takeda
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Pioglitazone + atorvastatin is a combination of two small molecule drugs used together, primarily in research and clinical practice, to address both dyslipidemia and insulin resistance. Pioglitazone is a thiazolidinedione antihyperglycemic agent that acts as an agonist at the peroxisome proliferator-activated receptor gamma (PPARγ), improving insulin sensitivity and glycemic control in type 2 diabetes mellitus[1][4][5]. Atorvastatin is an HMG-CoA reductase inhibitor (statin) that lowers cholesterol levels by inhibiting the rate-limiting step in cholesterol biosynthesis, thereby reducing low-density lipoprotein (LDL) cholesterol and overall cardiovascular risk[8]. The combination has been studied for its potential additive effects on lipid profiles, inflammation reduction, and improvement of insulin resistance in patients with or without diabetes who have cardiovascular disease[2].
- Brand names
- Piat
- Other names
- pioglitazone + atorvastatin
02
Targets
PPARG (Peroxisome proliferator-activated receptor gamma)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)
Beyond the preview
Go deeper on pioglitazone + atorvastatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pioglitazone + atorvastatin.